Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on September 30, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). License grants Ascendis worldwide rights to commercialize TransCon CNP, including Yuviwel, across all indications.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- License grants Ascendis worldwide rights to commercialize TransCon CNP, including Yuviwel, across all indications
- BioMarin receives royalties of 20% on U.S. sales and 18% on EU, Brazil and South Korea sales through May 2030
- Agreement converts the prior term sheet into a definitive arrangement, effective August 28, 2026
- Pending patent litigation dismissed with prejudice, reducing legal uncertainty but ending BioMarin’s pre-effective-date infringement claims
- Ascendis cannot challenge BioMarin’s patents and both parties agree to regulatory non-interference terms
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.